Vance Shrugs Off Backlash After Trump Says Americans' Finances Don't Factor Into Iran War "Even A Little Bit" Just before leaving to China on Tuesday, President Trump fielded question from the media and issued some shocking remarks which are sure to hurt, not help Republicans, during a week in which the Iran war hits the 75-day mark. President Trump conceded that the financial situation for Americ...
Vance Shrugs Off Backlash After Trump Says Americans' Finances Don't Factor Into Iran War "Even A Little Bit" Just before leaving to China on Tuesday, President Trump fielded question from the media and issued some shocking remarks which are sure to hurt, not help Republicans, during a week in which the Iran war hits the 75-day mark. President Trump conceded that the financial situation for Americans was not a factor in his decision-making when it came to Iran , at a moment Americans are alarmed at steadily rising gas prices, and the potential that the cost of everything from groceries to other basic staples could go up. The real surprise was that he didn't even try dodge the question or massage the topic like many politicians would choose to do, instead he emphasized: "Not even a little bit." "The only thing that matters, when I’m talking about Iran, they can’t have a nuclear weapon. I don't think about Americans' financial situation. I don’t think about anybody . I think about one thing: we cannot let Iran have a nuclear weapon… that’s the only thing that motivates me," he added. Watch: President Trump is asked how much he considers Americans' financial situation when negotiating with Iran: "Not even a little bit. The only thing that matters is they can't have a nuclear weapon. I don't think about Americans’ financial situation. I don't think about anybody." pic.twitter.com/BFxqVtZgQr — The American Conservative (@amconmag) May 12, 2026 Congressional GOP members are no doubt squirming in wake of these blunt comments, and Trump's own staff surely wasn't thrilled. Trump didn't so much as hesitate in his remarks, and midterm elections are coming up fast, with the Iran conflict and Hormuz showdown showing no signs of abating. Some have argued that Trump as Commander-in-Chief is in 'war mode' and so doesn't want to tip his cards or let the Iranians perceive that they have leverage and can impose a political cost, especially amid talks and stalled negotiations. But the ...
In this article 7011.T-JP Follow your favorite stocks CREATE FREE ACCOUNT SAN ANTONIO, ZAMBALES, PHILIPPINES - APRIL 28: A Japanese Self-Defense Forces personnel carried a Japanese national flag in front of missile systems, during an Integrated Air and Missile Defense (IAMD) drill, as part of the ongoing Balikatan (Shoulder-Shoulder) multinational exercise, at a naval base in San Antonio, Zambales...
In this article 7011.T-JP Follow your favorite stocks CREATE FREE ACCOUNT SAN ANTONIO, ZAMBALES, PHILIPPINES - APRIL 28: A Japanese Self-Defense Forces personnel carried a Japanese national flag in front of missile systems, during an Integrated Air and Missile Defense (IAMD) drill, as part of the ongoing Balikatan (Shoulder-Shoulder) multinational exercise, at a naval base in San Antonio, Zambales, Philippines, on April 28, 2026. The IAMD exercise, which sees the deployment of troops and missile systems from the United States and Japan, comes at a time of escalating tensions in the disputed South China Sea and the Taiwan Strait, with the Chinese People's Liberation Army increasing military activities in the water and Beijing denouncing Tokyo's strengthened defense cooperation with the Philippines. (Photo by Daniel Ceng/Anadolu via Getty Images) Anadolu | Anadolu | Getty Images Japan easing decades-old restrictions on arms exports opens a big opportunity for the country's defense industry in a world increasingly hungry for weapons. The global conditions seem favorable. On April 27, SIPRI reported that global military spending hit a record of $2.89 trillion in 2025, the 11th straight year of increase. Countries are "desperate" to acquire weapons such as air defense missiles, artillery shells and armored vehicles, areas where Japan Inc. might expand its market share in the international defense economy, Hirohito Ogi, senior research fellow at the Tokyo-based Institute of Geoeconomics, told CNBC in an interview. South Korea may offer a template — defense companies there have had a roaring few years producing arms cheaper, faster, and of comparable quality to U.S. weapons, benefiting as the Russia-Ukraine war drags on — and the Iran war is likely to fuel demand even further. What's more, traditional U.S. partners are now looking for alternative defense suppliers amid surging demand and doubts over American alliance commitments. Japanese engineering is "top-tier," and its...
据报道,中国电动汽车初创企业小鹏汽车正与 大众汽车 及其他汽车制造商就收购欧洲一家工厂进行磋商。 此前数日,大众集团首席执行官奥博穆(Oliver Blume)表示,公司可能将在中国研发的车款引入欧洲市场,甚至与中国合作伙伴在欧洲共享产能。 小鹏汽车东北欧地区负责人程晓光(Elvis Cheng)在FT的“汽车未来”(Future of the Car)峰会上表示,小鹏汽车正与大众汽车洽谈,以探讨...
据报道,中国电动汽车初创企业小鹏汽车正与 大众汽车 及其他汽车制造商就收购欧洲一家工厂进行磋商。 此前数日,大众集团首席执行官奥博穆(Oliver Blume)表示,公司可能将在中国研发的车款引入欧洲市场,甚至与中国合作伙伴在欧洲共享产能。 小鹏汽车东北欧地区负责人程晓光(Elvis Cheng)在FT的“汽车未来”(Future of the Car)峰会上表示,小鹏汽车正与大众汽车洽谈,以探讨“我们是否有可能在欧洲找到一个地点”。 大众汽车持有小鹏汽车的股份,并在中国拥有三家合资伙伴——上汽集团 、一汽集团和江淮汽车。但这些合作伙伴目前在欧洲均不具备生产能力。 报道称,小鹏汽车也将考虑在欧洲新建工厂。“我们认为,并非所有工厂都能满足我们最新或未来产品的需求,”程晓光对FT表示,并补充说大众汽车的工厂“有些陈旧”。 责任编辑:王永生
Apple’s (AAPL) AI strategy has been quiet for a while, but things could change quickly. Wedbush analyst Dan Ives raised his 12-month price target on Apple to $400 from $350, making it the most bullish call among major Wall Street analysts, according to TheFly. The move shows a broader ...
Apple’s (AAPL) AI strategy has been quiet for a while, but things could change quickly. Wedbush analyst Dan Ives raised his 12-month price target on Apple to $400 from $350, making it the most bullish call among major Wall Street analysts, according to TheFly. The move shows a broader ...
(RTTNews) - The Malaysia stock market turned lower again on Wednesday, one day after ending the two-day losing streak in which it had slumped more than a dozen points or 0.6 percent. The Kuala Lumpur Composite Index now sits just above the 1,745-point plateau although it may boun
(RTTNews) - The Malaysia stock market turned lower again on Wednesday, one day after ending the two-day losing streak in which it had slumped more than a dozen points or 0.6 percent. The Kuala Lumpur Composite Index now sits just above the 1,745-point plateau although it may boun
Earnings Call Insights: Journey Medical (DERM) Q1 2026 Management View "We made solid progress in the first quarter of 2026, marking a strong start to what we believe will be a breakout year for Emrosi and Journey Medical." (Founder, President, CEO & Director Claude Maraoui) "We delivered Emrosi revenues of $6.3 million in Q1... as prescription volumes continue to grow and payer reimbursement impr...
Earnings Call Insights: Journey Medical (DERM) Q1 2026 Management View "We made solid progress in the first quarter of 2026, marking a strong start to what we believe will be a breakout year for Emrosi and Journey Medical." (Founder, President, CEO & Director Claude Maraoui) "We delivered Emrosi revenues of $6.3 million in Q1... as prescription volumes continue to grow and payer reimbursement improves." (Founder, President, CEO & Director Maraoui) "In April, we announced that we entered into an agreement with the third of the 3 largest PBM-owned or affiliated group purchasing organizations in the United States... With the big 3 contracts in place for Emrosi, over 169 million of the 192 million commercial lives in the nation now have access to Emrosi." (Founder, President, CEO & Director Maraoui) "Operationally, we plan to add up to 5 new sales professionals to our commercial team this year... and, importantly, the establishment of Emrosi as standard of care in the treatment of rosacea." (Founder, President, CEO & Director Maraoui) "Total revenue for the quarter was $16 million... Emrosi... generated $6.3 million in net revenue... We reported a GAAP net loss of $2.2 million or $0.08 per share... On a non-GAAP basis, adjusted EBITDA was positive $600,000... We ended the quarter with $27.2 million in cash." (CFO & Corporate Controller Joseph Benesch) Outlook "While we plan to offer detailed financial guidance later this year, we are confident that the business will not only deliver positive adjusted EBITDA, but will also generate positive EBITDA for the remainder of this year and for the foreseeable future." (Founder, President, CEO & Director Maraoui) "We believe the additional resources will increase our productivity... the potential launch of up to 2 new niche dermatology products later this year." (Founder, President, CEO & Director Maraoui) "We're not ready to announce anything yet, but we're in very deep discussions and far along in discussions with some of the n...
Earnings Call Insights: Cytosorbents (CTSO) Q1 2026 Management View CEO Phillip Chan said Cytosorbents is “positioning the company for future growth” while “strengthen[ing] and streamline[ing] the business,” emphasizing a “highly scalable razor blade type recurring revenue model” and reiterating that “CytoSorb is not currently approved or cleared in the United States or Canada,” while “DrugSorb-AT...
Earnings Call Insights: Cytosorbents (CTSO) Q1 2026 Management View CEO Phillip Chan said Cytosorbents is “positioning the company for future growth” while “strengthen[ing] and streamline[ing] the business,” emphasizing a “highly scalable razor blade type recurring revenue model” and reiterating that “CytoSorb is not currently approved or cleared in the United States or Canada,” while “DrugSorb-ATR remains an investigational device.” (CEO & Director Phillip Chan) Chan reported Q1 revenue “grew 2% year-over-year to $8.9 million” despite “temporary external headwinds,” highlighting “continued deceleration in our Direct International business outside Germany, which grew 13% year-over-year,” while noting Germany “sales declined” but “productivity has improved and customer engagement has strengthened under new leadership,” with plans to “selectively rebuild portions of the sales force.” (CEO & Director Chan) Chan said distributor sales were “negatively impacted by geopolitical disruption in the Middle East…surrounding the U.S. Iran war,” which “delayed approximately $0.5 million in expected orders,” and added gross margin “remained strong at 69%,” with the decline “intentional as we strategically slowed production levels to reduce inventory and improve working capital efficiency.” (CEO & Director Chan) CFO Peter Mariani stated, “operating expenses were $9.2 million…compared to $10.1 million a year ago,” and said costs reflect “initial benefits of our strategic headcount and cost reduction program implemented in the fourth quarter of last year,” adding, “we expect the costs will continue to decrease sequentially.” (Chief Financial Officer Peter Mariani) Chief Medical Officer Efthymios Deliargyris said FDA has requested “additional mechanistic data…together with the real world evidence” for DrugSorb-ATR’s new de novo submission, and characterized mechanistic data as “non-clinical outcome data…to support the mechanism of action of the device.” (Chief Medical Officer Efthymi...